5-(4-吡啶基)-戊酸乙酯 | 78775-05-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 5-(4-吡啶基)-戊酸乙酯
• 英文名称: ethyl 5-(4-pyridyl)-pentanoate
• 英文别名: ethyl 5-(4-pyridyl)pentanoate；ethyl 5-(pyridin-4-yl)pentanoate；ethyl 5-pyridin-4-ylpentanoate
• CAS: 78775-05-0
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: OLLCOCZJELZGBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-吡啶基)-戊酸乙酯 在 氯化亚砜 、 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 5-(4-Pyridinyl)-pentylchloride
  参考文献：
  名称：

  Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives

  摘要：

  The enzyme thromboxane (TX) synthetase is inhibited by pyridine. The beta-substituted pyridine derivatives showed higher inhibitory potency than the gamma-substituted ones having the same side chain. Among the beta-substituted derivatives containing the omega-carboxyalkyl group, the compounds with 6-8 carbon atoms in the side chain were especially effective. The derivatives holding the phenylene group in the side chain exhibited much higher inhibitory activity than those of the alkylene type. Among them, (E)-3-[4-(3-pyridylmethyl)phenyl]-2-methylacrylic acid hydrochloride (5a) had the highest potency (IC50 = 3 x 10(-9) M). The beta-substituted pyridine derivatives and 1-substituted imidazole derivatives which had the same side chain showed almost the same potency. The beta-substituted pyridine derivatives do not inhibit arachidonic acid cyclooxygenase or prostaglandin I2 synthetase, two other enzymes of the arachidonic cascade.

  DOI：

  10.1021/jm00142a006
• 作为产物：
  描述：

  4-(3-溴丙基)吡啶氢溴酸 生成 5-(4-吡啶基)-戊酸乙酯
  参考文献：
  名称：

  影响ω-吡啶基链烷醇，ω-吡啶基烷酰胺和ω-吡啶基烷基胺的碱性的结构因素

  摘要：

  本文件描述了通过常规方法制备（当不市售）和p ķ一个所述的α--determination，β-和pyridylethanamide的γ -异构体，3- pyridylpropanamide。4-吡啶基丁酰胺，5-吡啶基戊酰胺，吡啶甲醇，2-吡啶基乙醇，3-吡啶基丙醇，4-吡啶基丁醇，5-吡啶基戊醇，吡啶基甲胺，2-吡啶基乙胺，3-吡啶基-丙胺，4-吡啶基丁胺和5-吡啶基戊胺。尽管场效应解释了p K a随链长变化的许多变化，但在某些甲基和乙基同系物中，明显的感应效应是有效的。在P ķ一在属于α系列的一些较低的同系物中，分子内H键的递减影响也是明显的。

  DOI：

  10.1002/hlca.19820650621
• 作为试剂：
  描述：

  二甲羟胺盐酸盐 在 三甲基铝 、 5-(4-吡啶基)-戊酸乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 16.75h， 以82%的产率得到N-methoxy-N-methyl-5-pyridin-4-ylpentanamide
  参考文献：
  名称：

  带有两亲性侧链的4-烷基吡啶的分子内环化流形：螺二氢吡啶的构建或通过无水中间体的苯甲酸环化

  摘要：

  在用氯甲酸乙酯和亚化学计量的Ti（O i Pr）4处理后，具有亲核β-二羰基侧链的4-烷基吡啶已转化为螺二氢吡啶。或者，发现在反应介质中包含温和的碱有助于促进脱水碱中间体的产生。随后与亲电子侧链部分的醛醇状缩合，然后水解，以高收率递送苄基环化的吡啶。环化脱水碱中间体的原位氢化得到4-取代的哌啶。

  DOI：

  10.1021/jo301247c

文献信息

• [EN] DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR<br/>[FR] CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISE POUR PPAR
  申请人：BETHESDA PHARMACEUTICALS INC

  公开号：WO2005009437A1

  公开（公告）日：2005-02-03

  This invention provides new chemical entities useful for treating a variety of clinical disorders including those that areinfluenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5­adamantan-2-yl-pentanoic acid 2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.

  这项发明提供了新的化学实体，可用于治疗各种临床疾病，包括那些受过氧化物酶体增殖物激活受体（PPAR）活性影响的疾病。提供了这些化合物的结构以及设计、制造和使用这些化合物的方法。提供了在牛皮癣病例中使用这些化合物的治疗组合物的化合物和方法。提供了一个具有以下结构的示例化合物：5-金刚烷基-2-基戊酸2-[4-(2,4-二氧-噻唑啉-5-基-甲基)-苯氧基]-乙基}-甲基酰胺。
• Novel 1,8-naphthyridin-2(1h)-one derivatives
  申请人：——

  公开号：US20030036651A1

  公开（公告）日：2003-02-20

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R 1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R 2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。具有以下结构的化合物（1）：其中：A是未取代或选择性取代的5或6成员杂环芳基团或融合苯环，其中上述任何杂环芳基团融合到苯环中，B是碳或氮，R1是氢、低烷基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或氨基氮含基团，R2是氢、卤素、氰基、硝基、低烷硫基、低烷基硫氧基、低烷基磺酰基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或氨基氮含基团，m是1到8的整数，包括1和8；或其药学上可接受的盐具有选择性PDE IV抑制作用，并且可用作药物，优选为抗哮喘药物等。
• Pde IV inhibitors
  申请人：——

  公开号：US20040176365A1

  公开（公告）日：2004-09-09

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  这段话的目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。式(1)的化合物：其中A是亚甲基，低碳基亚甲基，羰基等，Y是含有氮、硫和氧中的一种或两种杂原子的5-或6成员杂芳基团，Z是i）融合环，其中任何5-或6成员杂芳基团融合到苯环中，或ii）苯基，可以是未取代或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员，但当A是亚甲基时，Y是从吡咯基，吡啶基等中选择的5-或6成员杂芳基团，Z是未取代或取代的苯基时，所述苯基上的取代基是氨基或含氨基氮的基团；或其药学上可接受的盐，具有优异的PDE IV抑制作用，是一种有用的药物，首选是抗哮喘药物等。
• PDE IV inhibitors
  申请人：Aska Pharmaceuticals Co., Ltd.

  公开号：US07115623B2

  公开（公告）日：2006-10-03

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  本发明旨在提供具有强效抗哮喘特性和优良安全性的选择性PDE IV抑制剂。化合物的结构式（1）：其中A为亚甲基，低碳基亚甲基，羰基等，Y为含有一或两个从氮，硫和氧中选择的杂原子的5或6元杂芳基基团，Z为i）融合环，其中任何5或6元杂芳基团融合到苯环上，或ii）苯基，可以是未取代的或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员所选择的，但当A为亚甲基，Y为从吡咯基，吡啶基等所选择的5或6元杂芳基团，Z为未取代或取代的苯基时，所述苯基上的取代基为氨基或含氨基氮的基团; 或其药学上可接受的盐，具有出色的PDE IV抑制作用，并且作为药物，特别是抗哮喘药物等非常有用。
• VEHICLE FOR THE TRANSPORT OF A CHOSEN MOLECULE TO A CELL
  申请人：Ruiters Herman Jozef Marcel

  公开号：US20080085273A1

  公开（公告）日：2008-04-10

  Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is coupled to the linker molecule and the linker molecule is coupled to the cell specific ligand and in which the SAINT-molecule is covalently bound to the linker molecule.

  一种用于将选择的分子运输到细胞的载体，包括通过静电相互作用与所选分子结合的SAINT分子，其中SAINT分子与连接分子耦合，并且连接分子与特定于细胞的配体耦合，且SAINT分子与连接分子共价结合。